Pharmaceutical
Alcon is the largest ophthalmic pharmaceutical company in the world. Our pharmaceuticals are used globally every day to treat millions of people who suffer from eye diseases and conditions such as glaucoma, eye infection, eye inflammation, eye allergies and ear infections. We've highlighted some of our flagship pharmaceutical products that are revolutionizing eye care and eye health.
Eye Allergies
Eye allergies, also known as allergic conjunctivitis, often result in red, swollen, itchy eyes that create a range of annoyances from mild to severe. These allergies can be caused by a number of situational or environmental factors – smoke or other pollution, animal hair and dander, and pollen from trees, grass and other plants.
PATADAY™ Ophthalmic Solution
PATADAY™ ophthalmic solution (olopatadine hydrochloride 0.2%) is Alcon's newest prescription allergy eye drop and is currently available only in the United States. With twice the concentration of PATANOL® solution, it is the first eye drop approved for once-a-day dosing for ocular itching associated with allergic conjunctivitis.
Wait 10 minutes after using PATADAY™ solution before inserting contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age three. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of PATADAY™ solution is headache, but patients may also experience blurred vision, burning, stinging or nausea, as well as other effects. Some of these events may be related to the underlying condition itself and not therapy. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
For more information visit the U.S. Web site at www.pataday.com.
U.S. Product Insert
PATADAY™ Ophthalmic Solution [PDF]
PATANOL® / OPATANOL® Ophthalmic Solution
PATANOL® ophthalmic solution (olopatadine hydrochloride ophthalmic solution 0.1%), also known in many countries as OPATANOL® solution, is the world's leading prescription eye drop used to treat the signs and symptoms of allergic conjunctivitis including itching, redness, chemosis, tearing and lid swelling.
Wait 10 minutes after using PATANOL® solution before inserting contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age three. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of PATANOL® solution is a headache, but patients may also experience blurred vision, burning, stinging or nausea, as well as other effects. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
PATANOL® Ophthalmic Solution [PDF]
Eye Infections
Eye infections can range from common ailments, such as pink eye or conjunctivitis, to serious and sight-threatening conditions. Causes can include bacteria, complications with contact lenses or complications with surgery and other eye trauma. Since relatively benign infections can develop into serious disorders and cause significant eye damage, they should be treated aggressively.
VIGAMOX®* Ophthalmic Solution
VIGAMOX® solution (moxifloxacin HCI ophthalmic solution 0.5% as base) is an antibiotic used to treat the most common eye infection, bacterial conjunctivitis, commonly called "pink eye."
Do not wear contact lenses while using VIGAMOX® solution. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age one. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of VIGAMOX® solution is decreased visual acuity, but patients may also experience burning or stinging, red or itchy eyes, or rash, as well as other effects. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
VIGAMOX®* Ophthalmic Solution [PDF]
* Licensed to Alcon, Inc. by Bayer HealthCare, AG.
Eye Inflammation
Eye inflammation most commonly occurs in response to eye surgery, which while necessary, can upset the delicate tissue of the eye. But it can also occur as a result of infection, allergy, or eye trauma, such as a blow to the eye. Generally, with regard to inflammation, physicians work proactively by prescribing an anti-inflammatory drug.
NEVANAC® Ophthalmic Suspension
NEVANAC® suspension (nepafenac ophthalmic suspension 0.1%) treats eye pain and inflammation resulting from cataract surgery.
Do not wear contact lenses while using NEVANAC® suspension. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age 10. Caution should be used when administering this drug to pregnant or nursing women. This drug should not be used in late pregnancy. The most common side effects of NEVANAC® suspension include decreased visual acuity, a feeling that something is in the eye, increased eye pressure or a sticky sensation, as well as other effects. If you experience any of these symptoms contact your doctor. As with all NSAIDs, this drug may delay ocular healing and prolonged use may result in corneal problems. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
NEVANAC® Ophthalmic Suspension [PDF]
TOBRADEX® Ophthalmic Suspension
TOBRADEX® Ophthalmic Suspension(tobramycin 0.3% and dexamethasone 0.1% sterile ophthalmic suspension and ointment) has been the most frequently prescribed anti-infective and anti-inflammatory combination drug on the market for 20 years. TOBRADEX® suspension is used to treat eye inflammation where infection or the risk of infection is present.
Do not wear contact lenses while using TOBRADEX® suspension. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients or by persons with viral or fungal infections of the eye. Safety and efficacy have not been determined in children under age two. Caution should be used when administering this drug to pregnant or nursing women. The most common side effects of TOBRADEX® suspension are lid itching and swelling, but patients may also experience elevated intraocular pressure (IOP) and delayed wound healing, as well as other effects. If you experience any of these symptoms contact your doctor. Prolonged use of this drug may result in a higher likelihood of fungal infection or secondary bacterial infection. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
TOBRADEX® Ophthalmic Suspension [PDF]
Ear Infection
Outer ear infections, scientifically referred to as otitis externa, are fairly common bacterial infections. Although bacteria in the outer ear canal is normal and healthy, it can develop into infection when the right conditions are present for it to thrive. Such conditions include when skin in the ear canal is injured or damaged, often from objects like cotton swabs, or when water gets trapped in the ear from activities like swimming. The infection creates swelling, which is often painful. Middle ear infections can develop as a result of colds or flu, when bacteria move into the middle ear from the nose or throat.
CIPRODEX®* Otic Suspension
CIPRODEX® Otic Suspension (ciprofloxacin 0.3% and dexamethasone 0.1%) is the only otic combination therapy that combines a steroid that reduces swelling with a fluoroquinolone antibiotic that fights infection in both the middle and outer ear.
Patients should try to keep the treated area dry and clean and should avoid getting the infected ear wet. Patients should not touch the bottle tip to any surface including the hand to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to ciprofloxacin or any other of its ingredients. Safety and efficacy have not been determined in children under six months of age. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of CIPRODEX® otic is ear discomfort. Other common side effects include itching of the ear and ear debris, as well as other effects. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
CIPRODEX® Otic Suspension [PDF]
* Licensed to Alcon, Inc. by Bayer HealthCare AG. CIPRODEX is a registered trademark of Bayer AG, licensed to Alcon, Inc. by Bayer AG.
Glaucoma
Glaucoma is one of the leading causes of blindness, which usually occurs as a result of elevated intraocular pressure (IOP). A disease without noticeable symptoms, glaucoma often results in late diagnosis and poor patient compliance with treatment. Glaucoma can easily be detected early, however, through a standard eye exam before there is any loss of vision. Today there are convenient treatments that can lower intraocular pressure (IOP).
TRAVATAN Z® Ophthalmic Solution
TRAVATAN Z® Ophthalmic solution (travoprost ophthalmic solution 0.004%) is used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who may be intolerant to other intraocular pressure lowering medications or for whom other medications do not sufficiently lower IOP. TRAVATAN Z® solution is a new formulation that replaces benzalkonium chloride (BAK) with a preservative system that is gentle to the ocular surface.
TRAVATAN Z® solution should not be administered while wearing contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by those with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of TRAVATAN Z® solution is red eyes, but patients may also experience decreased visual acuity, eye pain and blurred vision, as well as other effects. If you experience any of these symptoms contact your doctor. Prostaglandins, such as TRAVATAN Z® solution, have been known to cause changes in eye color and eye lid skin color, as well as changes in eye lashes, which may be permanent. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
TRAVATAN Z® Ophthalmic Solution [PDF]
TRAVATAN® Ophthalmic Solution
TRAVATAN® solution (travoprost ophthalmic solution 0.004%) is a prescription eye drop used to reduce elevated intraocular pressure (IOP) in patients suffering from open-angle glaucoma or ocular hypertension and those for whom other medications do not sufficiently lower IOP.
TRAVATAN® solution should not be administered while wearing contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by those with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of TRAVATAN® solution is red eyes, but patients may also experience decreased visual acuity, eye pain and blurred vision, as well as other effects. If you experience any of these symptoms contact your doctor. Prostaglandins, such as TRAVATAN® solution, have been known to cause changes in eye color and eye lid skin color, as well as changes in eye lashes, which may be permanent. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
TRAVATAN® Ophthalmic Solution [PDF]
DUOTRAV™ Solution
DUOTRAV™ solution (40 micrograms/ml +5mg/ml eye drops). This product is not available in the United States. DUOTRAV™ solution combines two ocular hypertension reduction agents in one bottle. As they work together, DUOTRAV™ solution decreases intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers or prostaglandins.
DUOTRAV™ solution should not be administered while wearing contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by those with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of DUOTRAV™ solution is red eyes, but patients may also experience decreased visual acuity, eye pain and blurred vision, as well as other effects. If you experience any of these symptoms contact your doctor.
AZOPT® Ophthalmic Suspension
AZOPT® Ophthalmic suspension (brinzolamide ophthalmic suspension 1%) is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
AZOPT® suspension should not be administered while wearing contact lenses. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by those with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children. Caution should be used when administering this drug to pregnant or nursing women. The most common side effects of AZOPT® suspension are blurred vision and bitter, sour or unusual taste. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
AZOPT® Ophthalmic Suspension [PDF]
